{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3725","upperLimit":"15888","value":"13409.0"},{"groupId":"OG001","lowerLimit":"7108","upperLimit":"14028","value":"10156.0"},{"groupId":"OG002","lowerLimit":"17114","upperLimit":"58194","value":"26229.0"},{"groupId":"OG003","lowerLimit":"18827","upperLimit":"31112","value":"21498.0"},{"groupId":"OG004","lowerLimit":"36526","upperLimit":"93993","value":"51593.0"},{"groupId":"OG005","lowerLimit":"29640","upperLimit":"66623","value":"61190.0"},{"groupId":"OG006","lowerLimit":"32175","upperLimit":"70734","value":"48463.0"},{"groupId":"OG007","lowerLimit":"47149","upperLimit":"78604","value":"62876.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"2"}],"units":"Participants"}],"title":"BT062 plasma concentration Cycle 1 - Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9427","upperLimit":"9427","value":"9427.0"},{"groupId":"OG001","lowerLimit":"14193","upperLimit":"14193","value":"14193.0"},{"groupId":"OG002","lowerLimit":"23740","upperLimit":"31801","value":"27770.5"},{"groupId":"OG003","lowerLimit":"38144","upperLimit":"38144","value":"38144.0"},{"groupId":"OG004","lowerLimit":"92046","upperLimit":"92046","value":"92046.0"},{"groupId":"OG005","lowerLimit":"42123","upperLimit":"150233","value":"96178.0"},{"groupId":"OG006","lowerLimit":"50073","upperLimit":"50073","value":"50073.0"},{"groupId":"OG007","lowerLimit":"79248","upperLimit":"79248","value":"79248.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"title":"BT062 plasma concentration Cycle 4 - Cmax"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"description":"Multi-dose Pharmacokinetics properties of BT062 after intravenous (IV) Administration of escalating doses of BT062 as assessed by measuring intact BT062 conjugate.\n\nPlease note that not all subjects reached Cycle 4 due to early termination . A lower number of samples could be analyzed for Cycle 4.","dispersionType":"Full Range","groups":[{"description":"40 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG000","title":"BT062 40 mg/m²"},{"description":"50 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG001","title":"BT062 50 mg/m²"},{"description":"65 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG002","title":"BT062 65 mg/m²"},{"description":"80 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG003","title":"BT062 80 mg/m²"},{"description":"100 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG004","title":"BT062 100 mg/m²"},{"description":"120 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG005","title":"BT062 120 mg/m²"},{"description":"140 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG006","title":"BT062 140 mg/m²"},{"description":"160 mg/m² BT062 was administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.","id":"OG007","title":"BT062 160 mg/m²"}],"paramType":"MEDIAN","populationDescription":"Safety Population: The Safety population included all subjects who were enrolled and received at least\n\n1 dose of BT062 (n = 35).","reportingStatus":"POSTED","timeFrame":"Starting with first study drug administration until 30-day follow-up visit (average 4.99 months).","title":"Multi-dose Pharmacokinetics Properties of BT062 - Cmax","type":"SECONDARY","unitOfMeasure":"ng/ml"}